Type: Leukaemia
Dr Donia Moujalled and the team are testing a new antibody–drug conjugate (ADC) designed to deliver a powerful anticancer drug directly into leukaemia cells while limiting harm to healthy cells.
Prof John Pimanda and the team are aiming to help existing treatments work better for people with acute myeloid leukemia (AML), especially those who do not respond well to current medicines.
A/Prof Charles de Bock and his team are developing new immune-based treatments that help the body’s own immune system find and destroy leukaemia cells.
Professor Pimanda and his team have discovered that there are key differences in the cancer cells between patients who respond to chemotherapy compared to those who don’t.
If successful, this project will generate clinically translatable approaches to enhance AML therapy ready for progression to clinical trials to improve outcomes for AML patients.
Dr Jenny Wang and her team have discovered a key self-renewal pathway essential for the survival of leukaemia-initiating cells.
In this project, Professor Lock and his team will investigate lncRNAs specifically in childhood AML.
Dr Wang will investigate and detail how leukaemic stem cells are able to survive and renew.
This research will pave the way for the development of a less invasive and personalised diagnostic tests to detect cancer relapse in children with ALL.
This project will narrow in on a specific gene regulation process known to play a role in the cancer development.